Balance Sheet Components

6 Months Ended

Jun. 30, 2023

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Components

Balance Sheet Components

Cash, Cash Equivalents and Restricted Cash

A reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the amount reported within the condensed consolidated statements of cash flows is as follows (in thousands):

	June 30, 2023		December 31, 2022
Cash and cash equivalents	$	53,271	$	73,456
Restricted cash	3,954		3,954
Total cash, cash equivalents and restricted cash	$	57,225	$	77,410

Property and Equipment

Property and equipment consisted of the following (in thousands):

	June 30, 2023		December 31, 2022
Leasehold improvements	$	25,801	$	25,866
Laboratory equipment and office furniture	23,979		23,807
Computer equipment	1,433		1,433
Construction-in-progress	335		284
Total property and equipment, gross	51,548		51,390
Less: accumulated depreciation and amortization	(43,788)		(42,894)
Total property and equipment, net	$	7,760	$	8,496

Depreciation expense was $0.6 million and $1.2 million for the three and six months ended June 30, 2023, respectively, compared to $1.4 million and $2.8 million for the same periods in 2022.

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2023		December 31, 2022
Clinical trials and research and development costs	$	8,553	$	14,597
Personnel-related costs	4,714		9,181
Accrued expenses	3,222		3,834
Manufacturing costs	2,639		6,026
Total accrued liabilities	$	19,128	$	33,638